Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS Pharmaceuticals's operating cash flow per share for the
six
months ended in Dec. 2025 was A$-0.01.
BLS Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.01.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 56.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for BLS Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:
ASX:BLS'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -74.7 Med: 42.3 Max: 69.6
Current: 56.8
During the past 13 years, BLS Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 69.60% per year. The lowest was -74.70% per year. And the median was 42.30% per year.
ASX:BLS's 3-Year OCF Growth Rate is ranked better than 88.39% of 1137
companies
in the Biotechnology industry
Industry Median: 17
vs ASX:BLS: 56.80
BLS Pharmaceuticals Operating Cash Flow per Share Related Terms
BLS Pharmaceuticals Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals Operating Cash Flow per Share Chart
ASX:BLS vs VRTX, REGN, RVMD: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, BLS Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of A$0.01 mean?
BLS Pharmaceuticals (ASX:BLS) has a Operating Cash Flow per Share of A$0.01 as of Dec. 2025. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on BLS Pharmaceuticals and its competitors. According to the industry distribution chart, BLS Pharmaceuticals ranks #132 out of 1137 companies in the Biotechnology industry, placing it in the top 11.6%.
Is BLS Pharmaceuticals' Operating Cash Flow per Share too high?
BLS Pharmaceuticals' current Operating Cash Flow per Share is A$0.01. Based on the distribution chart, BLS Pharmaceuticals ranks #132 out of 1137 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Operating Cash Flow per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #132 out of 1137 companies for Operating Cash Flow per Share. This places BLS Pharmaceuticals in the top 12% of its industry — outperforming the majority of peers. The industry median Operating Cash Flow per Share is 17.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 17.00, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 17.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current Operating Cash Flow per Share is A$0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.71, compared to a current price of A$0.92 — trading 29.6% above its estimated fair value. The current Operating Cash Flow per Share is A$0.01. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current Operating Cash Flow per Share is A$0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.92 is trading 29.6% above its estimated GF Value™ of A$0.71.
GuruFocus considers BLS Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ASX:BLS:
Operating Cash Flow per Share: A$0.01
GF Value™: A$0.71 vs. price of A$0.92 (29.6% above fair value)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
